Combined Modality Therapy
"Combined Modality Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
| Descriptor ID |
D003131
|
| MeSH Number(s) |
E02.186
|
| Concept/Terms |
Combined Modality Therapy- Combined Modality Therapy
- Multimodal Treatment
- Multimodal Treatments
- Treatment, Multimodal
- Treatments, Multimodal
- Therapy, Combined Modality
- Combined Modality Therapies
- Modality Therapies, Combined
- Modality Therapy, Combined
- Therapies, Combined Modality
|
Below are MeSH descriptors whose meaning is more general than "Combined Modality Therapy".
Below are MeSH descriptors whose meaning is more specific than "Combined Modality Therapy".
This graph shows the total number of publications written about "Combined Modality Therapy" by people in this website by year, and whether "Combined Modality Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 16 | 16 |
| 1996 | 0 | 17 | 17 |
| 1997 | 0 | 11 | 11 |
| 1998 | 0 | 18 | 18 |
| 1999 | 0 | 7 | 7 |
| 2000 | 0 | 16 | 16 |
| 2001 | 2 | 19 | 21 |
| 2002 | 1 | 15 | 16 |
| 2003 | 0 | 27 | 27 |
| 2004 | 0 | 20 | 20 |
| 2005 | 0 | 32 | 32 |
| 2006 | 0 | 29 | 29 |
| 2007 | 1 | 32 | 33 |
| 2008 | 0 | 44 | 44 |
| 2009 | 0 | 23 | 23 |
| 2010 | 0 | 35 | 35 |
| 2011 | 0 | 35 | 35 |
| 2012 | 0 | 22 | 22 |
| 2013 | 1 | 40 | 41 |
| 2014 | 0 | 32 | 32 |
| 2015 | 1 | 34 | 35 |
| 2016 | 0 | 53 | 53 |
| 2017 | 3 | 49 | 52 |
| 2018 | 3 | 41 | 44 |
| 2019 | 2 | 50 | 52 |
| 2020 | 0 | 38 | 38 |
| 2021 | 2 | 25 | 27 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 9 | 9 |
| 2024 | 0 | 12 | 12 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Combined Modality Therapy" by people in Profiles.
-
Metabolic Effects of Testosterone Added to Intensive Lifestyle Intervention in Older Men With Obesity and Hypogonadism. J Clin Endocrinol Metab. 2025 Feb 18; 110(3):e814-e826.
-
Debate: Improvements in Systemic Therapies for Liver Metastases Will Increase the Role of Locoregional Treatments. Hematol Oncol Clin North Am. 2025 Feb; 39(1):207-220.
-
Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma. Clin Cancer Res. 2025 Jan 17; 31(2):258-265.
-
The Landmark Series: The Future of Pancreatic Cancer Clinical Trials. Ann Surg Oncol. 2025 Apr; 32(4):2777-2785.
-
Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer. Expert Opin Biol Ther. 2025 Jan-Feb; 25(2):149-159.
-
Next-generation combination approaches for immune checkpoint therapy. Nat Immunol. 2024 Dec; 25(12):2186-2199.
-
Standalone middle meningeal artery embolization versus middle meningeal artery embolization with concurrent surgical evacuation for chronic subdural hematomas: a multicenter propensity score matched analysis of clinical and radiographic outcomes. J Neurointerv Surg. 2024 Nov 22; 16(12):1313-1319.
-
Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas. Viruses. 2024 Nov 14; 16(11).
-
Ten-Year Outcome of a Randomized Trial: Cytoreduction and HIPEC with Mitomycin C Versus Oxaliplatin for Appendiceal Neoplasm with Peritoneal Dissemination. Ann Surg Oncol. 2025 Feb; 32(2):679-686.
-
Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nat Med. 2025 Jan; 31(1):176-188.